LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas. At the conference, John Kilcoyne, ReVision Optics President and Chief Executive Officer, presented an overview of clinical data from 344 patients followed for 24 months
Prompted by a rise in children’s eye injuries from toy guns, eye doctors urge parents to prioritize their kids’ eye safety when buying toys over the holidays.
In much the same way PAC-MAN® gobbles through an intense maze of dots eating and destroying its aggressors, researchers from the Charles E.
The FDA has released a final guidance document for industry and FDA staff on devices to treat glaucoma.“Premarket studies of implantable minimally invasive glaucoma surgical (MIGS) devices” provides initial recommendations of nonclinical and clinical studies to support the development of premarket approval applications for MIGS devices, the document said.
FLORENCE, Italy — At the FLOREtina meeting, Antonio Capone Jr, MD, talks about telemedicine as it applies to monitoring of infants at risk for retinopathy of prematurity. Capone has contributed to development of this type of screening, which he and colleagues initially undertook to study in clinical trials more than 15 years ago.
Valeant Pharmaceuticals International announced today in a press release new fulfillment agreements in which Valeant will reduce prices of its branded prescription-based dermatological and ophthalmological products by 10%.The plan includes more than 8,…